Study of VB4-845 Injection for Treating Patients With Non-muscle Invasive Bladder Cancer

Non-Muscle Invasive Bladder Cancer Clinical Trial

Official title:

An Open-Label, Single Arm, Multicenter Study to Evaluate the Efficacy and Safety of Intravesical VB4-845 Injection in Patients With Non-Muscle Invasive Bladder Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04859751
• Other study ID #: VB4-845-CN-001
• Status: Recruiting
• Phase: Phase 3
• Start date: March 23, 2021
• Est. completion date: December 2023

Study information

• Verified date: April 2021
• Source: Qilu Pharmaceutical Co., Ltd.
• Contact: Oliver Kong, CMO
• Phone: 0531-83129659
• Email: oliver.kong[@]qilu-pharma.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Because of the high risk for development of muscle invasive disease, cystectomy is recommended for CIS, high-grade Ta and T1 patients who experience disease recurrence following intravesical therapy. VB4-845 injection is an experimental agent that may provide an alternative to cystectomy

Description:

Bladder cancer is the 6th most common cancer in the United States, affecting more men than women. The usual first treatment for NMIBC (Ta, T1,and CIS) is transurethral resection of the bladder tumors followed by intravesical immunotherapy, most commonly with bacillus Calmette-Guérin (BCG).

Because of the high risk for development of muscle invasive disease, cystectomy is recommended for CIS and high-grade Ta and T1 patients who experience disease recurrence following intravesical therapy. For patients unable or unwilling to undergo cystectomy, treatment options are limited.

VB4-845 injection is a recombinant fusion protein produced in Escherichia coli (E. coli) that expresses a humanized single-chain antibody fragment specific for the epithelial cell adhesion molecule (EpCAM) antigen linked to exotoxin A (ETA[252-608]). Once bound to the EpCAM antigen on the surface of carcinoma cells, Vicinium is internalized through an endocytic pathway. The ETA(252-608) is cleaved off and induces cell death by irreversibly blocking protein synthesis.

This is an open-label, non-randomized, multicenter bridging study in Chinese patients with NMIBC, specifically CIS (with or without papillary disease), high-grade Ta or any grade T1 papillary disease, who have previously failed BCG treatment (i.e., not those who are intolerant) with or without interferon. The study consists of a Screening period, a 12-week Induction Phase, and a Maintenance Phase of up to 21 monthly cycles for a total treatment period of up to104 weeks.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 53
• Est. completion date: December 2023
• Est. primary completion date: June 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Histologically-confirmed non muscle-invasive urothelial carcinoma (transitional cell carcinoma) of the bladder.

2. Subjects must have received adequate BCG treatment defined as at least 2 courses of BCG, i.e., at least one induction and one maintenance course or at least 2 induction courses.

3. The subject's disease is refractory or has relapsed following adequate BCG treatment.

4. Male or non-pregnant, non-breastfeeding female, age 18 years or older at date of consent.

5. All women of childbearing potential (WOCBP) must have a negative pregnancy test within 7 days of the first dose of study therapy.

6. All sexually active subjects agree to use barrier contraception (i.e., condoms) while receiving study treatment and for 120 days following their last dose of study treatment.

7. Karnofsky performance status = 60.

8. Ability to understand and sign an Independent Ethics Committee-or Institutional Review Board-approved informed consent document.

Exclusion Criteria:

1. The subject is pregnant or breastfeeding.

2. Evidence of urethral or upper tract transitional cell carcinoma (TCC) within the past 2 years.

3. Subjects with hydronephrosis, except for those subjects where hydronephrosis has been longstanding and diagnostic evaluation at Screening shows no evidence of tumor.

4. Any intravesicular or other chemotherapy treatment within 2 weeks or any investigational agent within 4 weeks prior to the initial dose of study drug.

5. History of recurrent severe urinary tract infections (UTIs) per investigator judgment. Subjects with a current UTI requiring antibiotic treatment may defer the initiation of Vicinium treatment on Day 1 until resolution of the UTI.

6. he subject has a diagnosis of another malignancy within 2 years before the first dose of study treatment.

7. A QTc interval of >470 msec by the Fridericia formula (QTcF), at the Screening ECG.

8. Subjects who, in the opinion of the Investigator, cannot tolerate intravesical administration or intravesical surgical manipulation (cystoscopy, biopsy) due to the presence of serious comorbid condition(s).

9. Local or severe allergy to any components of the drug regimen.

Related Conditions & MeSH terms

• Non-Muscle Invasive Bladder Cancer
• Urinary Bladder Neoplasms

Intervention

Drug:
• VB4-845 Injection
Intravesical administration of VB4-845 Injection.

Locations

Country	Name	City	State
China	Fudan University Shanghai Cancer Center	Shanghai

Sponsors (1)

Lead Sponsor	Collaborator
Qilu Pharmaceutical Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Complete response rate	Complete response rate in patients with CIS with or without resected papillary disease following initiation of VB4-845 injection therapy	up to 6 months
Secondary	Recurrence-free rate	Recurrence-free (RF) rate in patients with high-grade Ta or any grade T1 papillary disease (without CIS)	up to 6 months
Secondary	Complete response rate	Complete response rate in patients with CIS with or without resected papillary disease following initiation of VB4-845 injection therapy	up to 3 months
Secondary	Recurrence-free rate	Recurrence-free (RF) rate in patients with high-grade Ta or any grade T1 papillary disease (without CIS)	up to 3 months
Secondary	Number of participants with treatment-related adverse events as assessed by CTCAE v5.0	Frequency and severity of adverse events. Including adverse events (AEs), change in physical examination findings, change in vital signs, clinical laboratory testing for systemic safety,including liver function, renal function, compelete blood count, and clinical chemistries.	Every 4 weeks up to 104 weeks